Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
IPO Year:
Exchange: NASDAQ
Website: amedisys.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2024 | $101.00 | Buy → Hold | Deutsche Bank |
| 7/1/2024 | Outperform → Mkt Perform | William Blair | |
| 6/7/2023 | $97.00 | Buy → Hold | Truist |
| 4/21/2023 | $87.00 | Neutral | Cantor Fitzgerald |
| 3/13/2023 | $93.00 | Equal Weight | Barclays |
| 10/27/2022 | Outperform → Mkt Perform | Raymond James | |
| 8/2/2022 | $145.00 → $95.00 | Neutral → Sell | UBS |
| 6/29/2022 | $128.00 | Hold | Stifel |
| 6/21/2022 | $145.00 → $102.00 | Neutral → Underperform | BofA Securities |
| 3/1/2022 | $168.00 | Sell → Neutral | UBS |
BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa
BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o
BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is inclusive of $11.5 million in costs associated with with our merger transactions, compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted s
BATON ROUGE, La., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and nine-month periods ended September 30, 2023. Three-Month Periods Ended September 30, 2023 and 2022 Net service revenue decreased $1.8 million to $556.2 million compared to $558.0 million in 2022. Prior year included $16.6 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $26.0 million compared to $25.6 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.79 compared to $0.79 in 2022. Adjusted Quarterly Results* Adjusted EBITDA of
BATON ROUGE, La., March 13, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), the leading provider of quality home health, hospice, and high-acuity care services, today announced that its Board of Directors has named Richard Ashworth as President, Chief Executive Officer, and member of the Board of Directors. Ashworth will assume the role on April 10, 2023, from Chief Executive Officer Paul Kusserow. Kusserow will remain Chairman of the Board for Amedisys and will provide support through the transition, with a continued strategic focus on Contessa Health. Ashworth is a pharmacist and a highly respected and accomplished healthcare executive with expertise in driving transformational g
BATON ROUGE, La., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Chairman and Chief Executive Officer (CEO) Paul Kusserow will retire as CEO on April 15th, 2022. Upon his retirement as CEO, Mr. Kusserow will continue to serve as Chairman of the Board of Directors, and current President and Chief Operating Officer (COO), Chris Gerard, will assume the role of President and CEO and join the Board of Directors following the succession planning process that began in early 2021. "Having the opportunity to be part of and lead Amedisys for the past seven years has genuine
Agape Care Group, a leading hospice and palliative care provider, announced today that it is has appointed Carry vandenMaagdenberg as its Chief Technology and Innovation Officer and welcomes Matt Winer to the company as its Chief Operations Officer. Both leaders are health care industry veterans who will lead Agape Care Group forward as it continues to serve a growing number of patients across the Southeast region. Winer joins Agape Care Group from LHC Group (NASDAQ:LHCG) where he led the company's Home Health Division in the Northeast. He has health care experience in South Carolina, having served in operational leadership roles for MUSC Health based in Charleston. He has also led teams i
4 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
3 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
4 - AMEDISYS INC (0000896262) (Issuer)
8-K - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
DEF 14A - AMEDISYS INC (0000896262) (Filer)
10-Q - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
10-Q - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
8-K - AMEDISYS INC (0000896262) (Filer)
Deutsche Bank downgraded Amedisys from Buy to Hold and set a new price target of $101.00
William Blair downgraded Amedisys from Outperform to Mkt Perform
Truist downgraded Amedisys from Buy to Hold and set a new price target of $97.00
Cantor Fitzgerald initiated coverage of Amedisys with a rating of Neutral and set a new price target of $87.00
Barclays initiated coverage of Amedisys with a rating of Equal Weight and set a new price target of $93.00
Raymond James downgraded Amedisys from Outperform to Mkt Perform
UBS downgraded Amedisys from Neutral to Sell and set a new price target of $95.00 from $145.00 previously
Stifel initiated coverage of Amedisys with a rating of Hold and set a new price target of $128.00
BofA Securities downgraded Amedisys from Neutral to Underperform and set a new price target of $102.00 from $145.00 previously
UBS upgraded Amedisys from Sell to Neutral and set a new price target of $168.00
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G/A - AMEDISYS INC (0000896262) (Subject)
SC 13G - AMEDISYS INC (0000896262) (Subject)
SC 13G - AMEDISYS INC (0000896262) (Subject)
BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors. "Every day, our employees bring warmth, compassion and clinical expertise into the homes of our patients, offering the care they need in the place they most want to be," said Richard Ashworth, President and Chief Executive Officer. "We are privileged to have exceptional clinicians who consistently exceed expectations, and it is a profound honor to recognize their incredible commitment." Each year, the company honors Home
BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month Periods Ended September 30, 2024 and 2023 Net service revenue increased $31.5 million to $587.7 million compared to $556.2 million in 2023.Net income attributable to Amedisys, Inc. of $16.9 million, which is inclusive of merger-related expenses totaling $16.7 million ($16.7 million, net of tax) compared to net income attributable to Amedisys, Inc. of $26.0 million, which is inclusive of merger-related expenses totaling $5.0 million ($4.7 million, net of tax) in 2023.Net income attribut
BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by Strategic Healthcare Programs (SHP) for achieving the highest overall HHCAHPS patient satisfaction or CAHPS Hospice caregiver satisfaction scores of all eligible SHP clients in 2023. This includes 14 care centers awarded Premier Performer, ranking in the top 5%, and 78 care centers awarded Superior Performer, ranking in the top 20%. Thirteen care centers achieved an award in each of the last 5 years of the SHPBest program. "Nothing we do is possible without our incredible ca
NASHVILLE, Tenn., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today, Contessa Health, a subsidiary of Amedisys Inc. (NASDAQ:AMED), announced they have been selected by the Centers for Medicare & Medicaid Services (CMS) to participate in a new Medicare alternative payment model designed to support people living with dementia and their caregivers. Under CMS' Guiding an Improved Dementia Experience (GUIDE) Model, Contessa will be one of almost 400 participants building Dementia Care Programs (DCPs) across the country, working to increase care coordination and improve access to services and supports, including respite care, for people living with dementia and their caregivers. "CMS is excited to
BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2024. Three-Month Periods Ended June 30, 2024 and 2023 Net service revenue increased $38.2 million to $591.2 million compared to $553.0 million in 2023.Net income attributable to Amedisys, Inc. of $32.3 million, which is inclusive of merger-related expenses totaling $11.9 million ($11.5 million, net of tax) compared to net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of merger-related expenses totaling $125.5 million ($125.5 million, net of tax) in 2023.Net income attributa
Has Nominated Seven Highly Qualified Independent Directors with Industry Expertise Who Can Help Drive Improved Operating Results Expresses Disappointment That Enhabit's Board Has Chosen Not to Engage Details Enhabit's Dramatic Operational Underperformance Reaffirms View of Substantial Unrecognized Value of Enhabit Files Preliminary Proxy Statement for 2024 Annual Meeting of Stockholders NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- AREX Capital Management, LP, together with its affiliates, the owners of approximately 4.9% of the shares of Enhabit, Inc. (NYSE:EHAB) ("Enhabit"), today issued an open letter to its fellow stockholders regarding the need for a major boardroom change at Enhabi
BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax), compared to $25.2 million in 2023.Net income attributable to Amedisys, Inc. per diluted share o
BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $19.3 million, which is inclusive of $11.5 million in costs associated with with our merger transactions, compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted s
BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infection testing, ultimately facilitating better patient care and outcomes. Advanced molecular testing revolutionizes the diagnosis and management of infections, as it delivers
BATON ROUGE, La., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and nine-month periods ended September 30, 2023. Three-Month Periods Ended September 30, 2023 and 2022 Net service revenue decreased $1.8 million to $556.2 million compared to $558.0 million in 2022. Prior year included $16.6 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $26.0 million compared to $25.6 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.79 compared to $0.79 in 2022. Adjusted Quarterly Results* Adjusted EBITDA of
BATON ROUGE, La., May 3, 2023 /PRNewswire/ -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2023. Three-Month Periods Ended March 31, 2023 and 2022 Net service revenue increased $11.1 million to $556.4 million compared to $545.3 million in 2022.Net income attributable to Amedisys, Inc. of $25.2 million compared to $31.7 million in 2022.Net income attributable to Amedisys, Inc. per diluted share of $0.77 compared to $0.97 in 2022.Adjusted Quarterly Results* Adjusted EBITDA of $57.8 million compared to $66.3 million
All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patients, Providers, Payers, and Care Teams Increases Access to High Quality Care for Communities Across the U.S. through a Unique National Clinical Platform Comprehensive Capabilities Across Alternate Site Care Spectrum Position Combined Company to Move Deeper into Value-Based Care Highly Attractive Combined Financial Profile Which Generated $6.2 Billion in Revenues and $622 Million in Adjusted EBITDA on a Combined Basis for Full Year 2022 Creates Stockholder Value Including Through Anticipated Annual Run-Rate Revenue and Cost Synergies of Approximately $75 Million by Year Three Following Clo
BATON ROUGE, La., April 20, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care, will report results for the first quarter ended March 31, 2023, after the market closes on May 3, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 4, 2023. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (888) 437-3179 (toll-free) or (862) 298-0702 (toll). A replay of the call will be available through June 4, 2023, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13737736. To access a live webcast of th
BOSTON , April 04, 2023 (GLOBE NEWSWIRE) -- HouseWorks LLC, a leading provider of personal care services in Massachusetts, New Hampshire, Pennsylvania, and Maine, today announces the acquisition of Associated Home Care, the Personal Care division at Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice, and high-acuity care. HouseWorks, in partnership with eCaring, joins the Amedisys personal care network and forms a care coordination partnership to deliver comprehensive, seamless care to the communities both organizations jointly serve. In addition to the HouseWorks footprint, eCaring provides mission critical software and services to over 75 home care agencies with 15
BATON ROUGE, La., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period and year ended December 31, 2022. Three-Month Periods Ended December 31, 2022 and 2021 Net service revenue increased $2.7 million to $562.0 million compared to $559.3 million in 2021.Net income attributable to Amedisys, Inc. of $31.7 million compared to $34.0 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.04 in 2021. Adjusted Quarterly Results* Adjusted EBITDA of $59.9 million compared to $64.8 million in 2021.Adjusted net service revenue of $562.0 million compared to $559.3 million in 2021
BATON ROUGE, La., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and nine-month periods ended September 30, 2022. Three-Month Periods Ended September 30, 2022 and 2021 Net service revenue increased $4.5 million to $558.0 million compared to $553.5 million in 2021.Net income attributable to Amedisys, Inc. of $25.6 million compared to $45.0 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.79 compared to $1.37 in 2021. Adjusted Quarterly Results* Adjusted EBITDA of $61.5 million compared to $72.4 million in 2021.Adjusted net service revenue of $558.9 million compared to $553.5 million in 2
BATON ROUGE, La., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the third quarter ended September 30, 2022, after the market closes on October 26, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on October 27, 2022. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through November 27, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID
BATON ROUGE, La., July 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and six-month periods ended June 30, 2022. Three-Month Periods Ended June 30, 2022 and 2021 Net service revenue decreased $6.3 million to $557.9 million compared to $564.2 million in 2021.Net income attributable to Amedisys, Inc. of $29.6 million compared to $80.1 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.91 compared to $2.43 in 2021. Adjusted Quarterly Results* Adjusted EBITDA of $74.4 million compared to $83.8 million in 2021.Adjusted net service revenue of $566.3 million compared to $557.6 million in 2021.Adjuste
BATON ROUGE, La., July 06, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the second quarter ended June 30, 2022, after the market closes on July 27, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on July 28, 2022. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (toll-free) or (412) 902-1028 (toll). A replay of the call will be available through August 28, 2022, by dialing (877) 660-6853 (toll-free) or (201) 612-7415 (toll) and entering access ID 13731294. A
BATON ROUGE, La., April 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three-month period ended March 31, 2022. Three-Month Periods Ended March 31, 2022 and 2021 Net service revenue increased $8.2 million to $545.3 million compared to $537.1 million in 2021.Net income attributable to Amedisys, Inc. of $31.7 million compared to $49.9 million in 2021.Net income attributable to Amedisys, Inc. per diluted share of $0.97 compared to $1.50 in 2021. Adjusted Quarterly Results* Adjusted EBITDA of $66.3 million compared to $78.6 million in 2021.Adjusted net income attributable to Amedisys, Inc. of $40.1 million compared to $51.1 million